Handelsbanken Fonder
ESPR

Handelsbanken Fonder’s Esperion Therapeutics ESPR Stock Holding History

Handelsbanken Fonder’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-4,358
Closed -$224K – 1456
2020
Q2 		$224K Buy
+4,358
New +$182K ﹤0.01% 1347

Other funds holding ESPR

BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Handelsbanken Fonder's ESPR Position: Q3 2020 in Review

Handelsbanken Fonder sold out of Esperion Therapeutics (ESPR) in Q3 2020, closing a stake of 4,358 shares — an estimated $224K sold.

Handelsbanken Fonder first reported a position in ESPR in Q2 2020 and held it in 1 quarter. The position peaked at $224K in Q2 2020. 166 funds tracked by Wall St. Rank hold ESPR as of Q3 2020.

  • Handelsbanken Fonder reported no remaining Esperion Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Handelsbanken Fonder sold 4,358 Esperion Therapeutics shares in Q3 2020, an estimated $224K.
  • Handelsbanken Fonder first reported a position in Esperion Therapeutics in Q2 2020 and held it in 1 quarter.
  • Handelsbanken Fonder's Esperion Therapeutics position peaked at $224K in Q2 2020.
  • 166 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q3 2020.

Based on Handelsbanken Fonder's 13F filing for Q3 2020, filed 13 Nov 2020.